Literature DB >> 17646088

Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.

Hui Wang1, Bo Zhang, Yuxing Ni, Joseph L Kuti, Baiyi Chen, Minjun Chen, David P Nicolau.   

Abstract

Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7-100%) and A. baumannii (66.0-86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9-86.6% in Southern China and 64.8-82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved < or =50% CFR against all bacterial species. Meropenem 2g every 8h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa. Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646088     DOI: 10.1016/j.ijantimicag.2007.06.005

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  10 in total

1.  Pharmacodynamic model for β-lactam regimens used in surgical prophylaxis: model-based evaluation of standard dosing regimens.

Authors:  XiangQing Song; MingHui Long
Journal:  Int J Clin Pharm       Date:  2018-08-16

2.  Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms.

Authors:  Wang Hengzhuang; Hong Wu; Oana Ciofu; Zhijun Song; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

3.  Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.

Authors:  Rong Chen; Qing Qian; Meng-Ru Sun; Chun-Yan Qian; Su-Lan Zou; Ming-Li Wang; Li-Ying Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-08       Impact factor: 2.441

4.  Imipenem Population Pharmacokinetics: Therapeutic Drug Monitoring Data Collected in Critically Ill Patients with or without Extracorporeal Membrane Oxygenation.

Authors:  Wenqian Chen; Dan Zhang; Wenwen Lian; Xiaoxue Wang; Wenwen Du; Zhu Zhang; Dongjie Guo; Xianglin Zhang; Qingyuan Zhan; Pengmei Li
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

5.  Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against gram-negative bacteria collected from Shenyang, China.

Authors:  Yun Zhuo Chu; Su Fei Tian; Bai Yi Chen; Hua Nian; Hong Shang; Guo Quan Sun
Journal:  BMC Infect Dis       Date:  2010-06-15       Impact factor: 3.090

6.  Meropenem Assessment before and after Implementation of a Small-Dose, Short-Interval Standard Dosing Regimen.

Authors:  Ivy Chow; Vincent Mabasa; Connor Chan
Journal:  Can J Hosp Pharm       Date:  2018-03-07

7.  Simulating moxalactam dosage for extended-spectrum β-lactamase-producing Enterobacteriaceae using blood antimicrobial surveillance network data.

Authors:  Chen Huang; Qingyi Shi; Beiwen Zheng; Jinru Ji; Chaoqun Ying; Xiao Yu; Hui Wang; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2019-05-08       Impact factor: 4.003

8.  In Vitro Activity of Various Sulbactam Compounds and Piperacillin/Tazobactam against Clinical Isolates of Different Gram-Negative Bacteria.

Authors:  Shunian Xiao; Chuyue Zhuo; Chao Zhuo
Journal:  Comput Math Methods Med       Date:  2021-11-25       Impact factor: 2.238

9.  Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.

Authors:  Ivan Chytra; Martin Stepan; Jan Benes; Petr Pelnar; Alexandra Zidkova; Tamara Bergerova; Richard Pradl; Eduard Kasal
Journal:  Crit Care       Date:  2012-06-28       Impact factor: 9.097

10.  Continuous infusion of meropenem in critically ill patients: practical considerations.

Authors:  Fabio Silvio Taccone
Journal:  Crit Care       Date:  2012-08-27       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.